1 / 51

Clinical Perspective on Citizen Petition

Clinical Perspective on Citizen Petition. NDAC / PADAC Joint Meeting Robert J. Meyer, MD Director, DPADP CDER / FDA May 11th, 2001. Clinical Perspective. Important Considerations for OTC Switch : The ability of the consumer to self-diagnose and/or self-manage

Patman
Download Presentation

Clinical Perspective on Citizen Petition

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Clinical Perspective on Citizen Petition NDAC / PADAC Joint Meeting Robert J. Meyer, MD Director, DPADP CDER / FDA May 11th, 2001

  2. Clinical Perspective Important Considerations for OTC Switch: • The ability of the consumer to self-diagnose and/or self-manage • Safety and effectiveness for drug used in OTC setting (i.e., without a “learned intermediary”)

  3. Clinical Perspective These important considerations are often addressed by: • OTC actual-use study; and/or • Label comprehension study

  4. Clinical Perspective • Allegra, Claritin and Zyrtec are all antihistamines, all approved to treat allergic rhinitis • FDA accepts allergic rhinitis as an appropriate OTC indication, and • FDA accepts antihistamines as appropriate for OTC use • FDA has established appropriate OTC labeling for antihistamine products

  5. Clinical Perspective Neither an actual-use study nor a labeling comprehension study is necessary for the OTC switch proposed FDA is not seeking advice on: • Allergic rhinitis as an OTC indication • On the effectiveness of Claritin, Zyrtec or Allegra in OTC setting

  6. Clinical Perspective • Focus of FDA clinical presentation is on safety and how the safety experiences bear on the decision for OTC availability • FDA performed full safety review • NDA data • Post-marketing data (AERS) • Other sources

  7. Safety Presentation • Elements of safety presentation: • NDA data • Standard safety data, cardiac safety evaluation, drug-interactions • Post-marketing experience • Case Review, Epidemiology • Focus for NDA on single ingredient compounds • AERS reports for include all formulations

  8. Safety Presentation - Caveats • Safety review is not intended to be comparative of the three agents • Safety review will not attempt to rigorously compare to OTC antihistamines • Safety review will help define the safety experience with these agents individually

  9. Safety Presentation - Caveats • Most definitive safety data are from NDA • Post-marketing data offers less definitive information about product safety • The use of epidemiology evaluations of AERS data can help place post-marketing data in perspective, but is not definitive

  10. NDA Data Introduction • Claritin (loratadine) • approved for marketing April 12, 1993 • Zyrtec (cetirizine) • approved for marketing Dec. 8, 1995 • Allegra (fexofenadine) • approved for marketing July 25, 1996

  11. NDA Safety Data • Numbers of Patients Exposed • Safety Experience in Clinical Trials • Cardiac Safety (in vitro, animals, human) • Drug Interactions

  12. NDA Safety Data Introduction Why the focus on cardiac safety and drug-drug interactions? • Issues for Seldane (terfenadine): • ECG / repolarization effects (QT interval) • Cases of malignant arrhythmias (TdP) • Problem was clinically manifest due to drug-drug interactions • Similar issues with Hismanal

  13. NDA Safety Data Introduction Cardiac Investigation of this potential for a new drug may include: • In vitro studies of ion (K+) channels and repolarization in isolated cardiac muscle • In vivo animal studies • Clinical data • e.g., high dose and drug interaction studies, clinical monitoring in clinical trials

  14. Claritin NDA Database • In the NDA database for loratadine over 90,000 patients exposed • Adverse event profile was consistent for an antihistamine given for allergic rhinitis • No significant clinical safety signals in original NDA

  15. Claritin NDA Database

  16. Claritin NDA Database • Somnolence was dose-related, with reporting of 10% with 20 mg QD, 12% with 40 mg QD • Pediatric studies (6 - 11 years) showed similar AE profile • Nervousness, hyperkinesia, wheezing and abdominal pain also reported • No significant safety concerns at the time of approval

  17. Claritin Cardiac Safety • In vitro testing (ion channel, myocardial cells) was negative • No QT or repolarization effects documented in animals • No significant cardiac AE’s seen in clinical trials (up to 160 mg) • No clinically meaningful effect on QTc documented in clinical studies

  18. Claritin Metabolic Considerations • Loratadine metabolized by CYP3A4, 2D6 • Drug interaction studies with erythromycin, cimetidine and ketoconazole showed some increase in loratadine and desloratadine AUCs • No clinically significant impact • Renal and hepatic insufficiency decrease clearance

  19. Zyrtec NDA Database • An Active metabolite of hydroxyzine • Over 3900 patients were treated in clinical trials with Zyrtec • Adverse event profile consistent with an antihistamine given for allergic rhinitis

  20. Zyrtec NDA Database

  21. Zyrtec NDA Database • Somnolence was dose-related • Other AEs reported in children at a rate higher than placebo in both doses: • abdominal pain, diarrhea, vomiting • somnolence in children 1.9% with 5 mg, 4.2% with 10 mg, placebo = 1.3% • No significant safety signals from original NDA

  22. Zyrtec Cardiac Safety • In vitro testing (myocytes, ion channels) revealed no effects at relevant concentrations • No significant QT or repolarization effects seen in whole animals • No significant cardiac AE’s seen in clinical trials, including 6 times the recommended dose • 1 of 4 safety-exposure studies showed an effect on the ECG • 9.1 msec increase in QTC using Bazett’s correction

  23. Zyrtec Metabolic Considerations • Renal excretion, the majority unchanged • No significant drug interactions • Renal impairment causes moderate decrease in clearance • Hepatic impairment causes small effect on clearance

  24. Allegra NDA Database • Acid metabolite (active) of terfenadine • Over 2,353 patients exposed to Allegra • AE profile was as expected given Allegra’s drug class and indications studied

  25. Allegra NDA Database

  26. Allegra NDA Database • Reporting of somnolence not dose-related • AE profile in Children additionally showed: • headaches, accidental injuries, cough, fever, pain, otitis media and URIs • No significant safety signals in original NDA

  27. Allegra Cardiac Safety • In vitro testing (ion channels, isolated myocytes) showed no evidence of repolarization effects • No whole animal effects even at high exposures • No significant cardiac events reported in clinical trials • No clinical ECG interval effects seen, even at doses up to 690 mg BID

  28. Allegra Metabolic Considerations • Fexofenadine minimally metabolized • Drug interaction studies showed small increase in AUC • No evidence of important changes in metabolism in special populations

  29. NDA summary • All three drugs with acceptable safety in NDAs • Work-up for cardiac effects reassuring • Claritin with some drug-drug interactions, but no apparent clinical consequences

  30. POST-MARKETING • Duration of marketing will affect total numbers of reports • Extent of use will affect total number of reports • Heightened sensitivities may affect number of reports

  31. POST-MARKETING • Databases first extensively queried up to 4/2000, updated for serious events • Overall, this assessment shows all 3 drugs to have a good post-marketing safety profile, though a few signals seen • No issues found in review that would warrant reconsideration of approval

  32. POST-MARKETING - OTC antihistamines • Review of literature, AERS database also performed • OTC antihistamines have acceptable safety profile • CNS and anticholinergic AEs common • Rare cases of seizures, liver failure, serious cardiac adverse events and other rare events have been noted

  33. POST-MARKETING – Claritin 4081 Spontaneous AEs for all loratadine products Most commonly reported events were: Drug ineffective Tachycardia Drug interaction Insomnia Headache Sedation Palpitations Dermatitis Dizziness Nervousness

  34. POST-MARKETING – Claritin Serious Cardiac events: • 86 cases were reviewed in depth • Patient ages ranged from 2 to 87 years • 38% of reports were for patients less than 50 years old • Large majority of cases occurred in setting of confounding factors

  35. POST-MARKETING – Claritin • Some hepatic terms are included in listing of in Claritin labeling • 5 cases of hepatic failure in AERS database • 3 of 5 had confounding factors • 2 of 5 not otherwise explained, without clear causality

  36. POST-MARKETING – Zyrtec 3096 Spontaneous AEs in database for cetirizine Most commonly reported events were: Drug ineffective Pruritus Sedation Drug Interaction Thrombocytopenia Asthenia Urticaria Headache Dermatitis Hypersensitivity

  37. POST-MARKETING – Zyrtec Thrombocytopenia (low blood platelets): • 1 case in NDA database • 170 cases in the AERS database • All but 11 cases were not plausibly linked to cetirizine use • Review of the 11 cases do not provide a clear link to the drug

  38. POST-MARKETING – Zyrtec • Seizures - 64 cases • 26 cases discounted as implausibly linked • 38 cases were reviewed in depth, 5 were not seizure events • Ages ranged from 3 to 79 years • 21 new onset / 12 pre-existing seizure

  39. POST-MARKETING – Zyrtec Serious cardiac events • 37 cases were reviewed in depth • Patient ages ranged from 3 to 80 years • More than half under 50 years • Majority of cases with confounding features

  40. POST-MARKETING – Allegra 1768 Spontaneous AEs for fexofenadine products Most commonly reported events were: Drug ineffective Sedation Nausea Insomnia Dizziness Palpitations Dermatitis Diarrhoea Headache Dyspnoea

  41. POST-MARKETING – Allegra Serious cardiac events • 39 cases reviewed • Age range from 15 to 81 years • Of the most serious cases, the majority had a prior cardiac history and/or concomitant drugs

  42. POST-MARKETING – Allegra Seizures • 17 of 30 cases were reviewed in depth • ages ranged from 22 to 80years old • 9 patients with no previous history • 10 patients on drugs known to cause seizures • 8 with dechallenge, 1 possible rechallenge

  43. POST-MARKETING • Some signals arise in AERS database • After careful review, each drug has some cases of cardiac events and seizures that cannot be otherwise explained • All these events occur with some background rate in the general population

  44. Epidemiology Assessment • The epidemiology staff within OPDRA estimated reporting rates for these 3 drugs vs. expected background incidences • Events examined • serious cardiac events • seizures • hepatotoxicity for loratadine

  45. Epidemiology Assessment • Background incidence rates were estimated for comparison purposes • Drug experience comes from a mixed-risk population • “Denominator” for rates inferred from actual use data

  46. Epidemiology Assessment • Serious Cardiac Events • estimated incidence of 44 per million person-years • New Onset Solitary Seizures • Estimated incidence of 90 per millionperson-years • Hepatic Failure • Estimated incidence of 1 to 2.3 per million person-years

  47. Epidemiology Conclusions: • The calculated reporting rates for all three drugs were comparable for serious cardiac events and seizures • Reporting rates are below background rate for all three drugs and all events • Due to limitations of the data and these analyses, a safety problem for one or more of these drugs cannot be excluded

  48. Overall Clinical/Regulatory Conclusions

  49. Overall Conclusions • Loratadine, fexofenadine, cetirizine have extensive, favorable marketing histories and safety profiles • FD&C Act sets criteria for when a drug should be Rx-only vs. OTC • The US market has OTC antihistamines available to treat symptoms of allergic rhinitis

  50. Overall Conclusions • BC/BS petition requests FDA to initiate a switch of three Rx antihistamines to OTC status • Available data for these drugs supports them being effective for allergic rhinitis • Some low-frequency safety “signals” do arise from the post-marketing experience • Weight of safety evidence is that all three drugs have a favorable safety profile

More Related